Sen. John Boozman Unloads Boston Scientific Corporation (NYSE:BSX) Stock

Senator John Boozman (Republican-Arkansas) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on July 13th, the Senator disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on June 4th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of iShares Expanded Tech-Software Sector ETF (BATS:IGV) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of (NYSE:TPYP) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 6/17/2026.
• Sold $1,001 – $15,000 in shares of Atmos Energy (NYSE:ATO) on 6/12/2026.
• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of iShares CMBS ETF (NYSEARCA:CMBS) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares Agency Bond ETF (NYSEARCA:AGZ) on 5/27/2026.

Boston Scientific Price Performance

Boston Scientific stock traded down $0.67 during trading on Friday, reaching $43.95. The company had a trading volume of 15,517,768 shares, compared to its average volume of 17,885,732. The firm has a market capitalization of $65.33 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 0.84 and a beta of 0.58. The firm’s 50-day simple moving average is $48.18 and its 200 day simple moving average is $65.87. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Leerink Partners reduced their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Mizuho decreased their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $79.84.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. Cary Street Partners Financial LLC increased its holdings in shares of Boston Scientific by 16.7% in the second quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock valued at $1,071,000 after purchasing an additional 3,597 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Boston Scientific by 28.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock worth $1,227,000 after acquiring an additional 6,427 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Boston Scientific by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock worth $2,106,000 after acquiring an additional 1,119 shares during the period. Simplify Asset Management Inc. raised its holdings in shares of Boston Scientific by 32.6% during the 2nd quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock worth $641,000 after acquiring an additional 3,690 shares during the period. Finally, Riversedge Advisors LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $320,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.